Lexeo Therapeutics, Inc. (LXEO) Form S-3 — Oct 29, 2026

Lexeo Therapeutics filed a new $300 million shelf registration statement on Form S-3 covering common stock, preferred stock, debt securities, warrants, subscription rights, purchase contracts and units, to be offered from time to time. The filing carries forward $135,387,220.20 of unsold securities from its prior S-3 (File No. 333-283781), which terminated upon effectiveness of this new registration statement. The shelf itself does not price any offering; terms, size and use of proceeds will be set in future prospectus supplements, so the immediate impact is potential rather than actual dilution.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.